Thymosin Alpha-1 5mg

Thymosin Alpha-1 Thymosin Alpha-1 (Tα1) is a naturally occurring 28-amino acid peptide derived from the thymus gland. It plays a pivotal role in modulating the immune system by promoting the development and function of T lymphocytes. Tα1 has been extensively studied for its potential therapeutic applications in enhancing immune responses and restoring immune function in various clinical settings.

Thymosin Alpha-1 Research

Thymosin Alpha-1 Modulates the Immune System

Thymosin alpha-1 (Ta1), isolated from the thymus gland, is a key regulator of immune function, crucial for T-cell maturation and adaptive immunity. Studies in thymectomized mice show Ta1 alone can restore immune function and prevent infection by activating immune signaling pathways and cytokine production. Ta1 enhances vaccine responses, particularly improving immunity from inactivated vaccines, potentially benefiting diseases like avian influenza and HIV.

Role in Sepsis and Neurodevelopment

Ta1 reduces mortality and complications in sepsis by modulating immune responses and is being explored as an adjuvant therapy. It also promotes nerve growth and cognitive function by affecting genes related to neuron development, favoring brain growth while suppressing inflammation and neuron dysfunction. This has implications for treating neurodevelopmental delays such as cerebral palsy.

Antifungal Activity and Dendritic Cell Regulation

Ta1 stimulates dendritic cell maturation, boosting fungal infection defense, particularly against aspergillus. By regulating dendritic cells—key antigen-presenting cells in skin, lungs, and GI tract—Ta1 influences immune function at a fundamental level.

Hepatitis and HIV Therapy

Approved in over 35 countries, Ta1 treats chronic hepatitis B and C and enhances vaccine efficacy for these viruses. In HIV patients, Ta1 helps restore immune regulation impaired by antiretroviral therapy and boosts CD8 T-cell release of factors that inhibit HIV infection and activation.

Blood Pressure and Cancer Research

Ta1 inhibits angiotensin converting enzyme (ACE), potentially reducing blood pressure and related cardiac and renal damage without typical ACE inhibitor side effects. In cancer, Ta1 shows antiproliferative effects, reducing tumor growth and metastasis in lung, breast, melanoma, liver, and colon cancers. When combined with chemotherapy, it improves progression-free survival without added toxicity. Long-acting Ta1 variants show enhanced effects in animal cancer models.

Pain Relief and Cystic Fibrosis

Ta1 reduces inflammatory pain by inhibiting pro-inflammatory cytokines, offering potential improved analgesia with fewer side effects. In cystic fibrosis, Ta1 decreases inflammation and enhances CFTR protein function, suggesting a promising therapeutic approach.

Dental Applications

Research indicates Ta1 improves healing and survival of replanted teeth after traumatic avulsion, potentially aiding dental trauma treatments.

Pharmacology and Usage

Ta1 has minimal side effects, with low oral and excellent subcutaneous bioavailability in mice; mouse dosages do not scale directly to humans. Ta1 for sale at Peptide Sciences is for research only, not human consumption. Purchase only if licensed.

Research Applications

Thymosin Alpha-1 is primarily utilized in research focusing on:

• Immune System Modulation: Investigating its role in enhancing T-cell-mediated immunity.
• Cancer Immunotherapy: Exploring its potential to augment anti-tumor immunity.
• Viral Infections: Studying its effects on viral replication and immune responses.
• Autoimmune Diseases: Evaluating its potential in modulating immune tolerance.

Product Specifications

• Form: Lyophilized (freeze-dried) powder for reconstitution.
• Dosage: Each vial contains 5mg of Thymosin Alpha-1.
• Purity: Typically ≥98%, ensuring high-quality material for research purposes.
• Packaging: Available in sealed vials containing 5mg of Thymosin Alpha-1 powder.
• Storage: Store lyophilized Thymosin Alpha-1 at temperatures below -18°C. After reconstitution, store at 4°C and use within 2-7 days.

Safety and Handling

Thymosin Alpha-1 is intended strictly for laboratory research and is not approved for human consumption. Handle with care, following appropriate safety protocols. Ensure proper storage conditions to maintain the integrity and efficacy of the compound.is a potent immune system regulator studied for its effects on infections, respiratory disorders, chronic hepatitis, and cancer. It enhances immune response and helps balance immune function. Derived from the thymus gland, this peptide supports natural defense mechanisms. Strengthen your immune system and promote resilience with Thymosin Alpha-1. Order now for targeted immune modulation!

Referenced Citations

1. R. King and C. Tuthill, “Immune Modulation with Thymosin Alpha 1 Treatment,” Vitam. Horm., vol. 102, pp. 151-178, 2016. 
2. C. Zhang et al., “Gene cloning, expression and immune adjuvant properties of recombinant fusion peptide Ta1-BLP on avian influenza inactivated virus vaccine,” Microb. Pathog., vol. 120, pp. 147-154, Jul. 2018. 
3. F. Pei, X. Guan, and J. Wu, “Thymosin alpha 1 treatment for patients with sepsis,” Expert Opin. Biol. Ther., vol. 18, no. sup1, pp. 71-76, 2018. 
4. G. Wang et al., “Immunopotentiator Thymosin Alpha-1 Promotes Neurogenesis and Cognition in the Developing Mouse via a Systemic Th1 Bias,” Neurosci. Bull., vol. 33, no. 6, pp. 675-684, Dec. 2017. 
5. L. Romani et al., “Thymosin α1 activates dendritic cells for antifungal Th1 resistance through Toll-like receptor signaling,” Blood, vol. 103, no. 11, pp. 4232-4239, Jun. 2004. 
6. L. Romani et al., “Thymosin alpha: an endogenous regulator of inflammation, immunity, and tolerance,” Ann. N.Y. Acad. Sci., vol. 1112, pp. 326-338, Sep. 2007. 
7. A. L. Goldstein and A. L. Goldstein, “From lab to bedside: emerging clinical applications of thymosin alpha 1,” Expert Opin. Biol. Ther., vol. 9, no. 5, pp. 593-608, May 2009. 
8. C. Matteucci et al., “Thymosin alpha 1 and HIV-1: recent advances and future perspectives,” Future Microbiol., vol. 12, pp. 141-155, 2017. 
9. C. Matteucci et al., “Thymosin α1 potentiates the release by CD8(+) cells of soluble factors able to inhibit HIV-1 and human T lymphotropic virus 1 infection in vitro,” Expert Opin. Biol. Ther., vol. 15 Suppl 1, pp. S83-100, 2015. 
10. J. Knarazmi-Khorassani, A. Asoode, and H. Tanzadenpanah, “Antioxidant and angiotensin-converting enzyme (ACE) inhibitory activity of thymosin alpha-1 (Ta1) peptide,” Bioorganic Chem., vol. 87, pp. 743-752, Jun. 2019. 
11. J. Knarazmi-Khorassani and A. Asooden, “Thymosin alpha-1; a natural peptide inhibits cellular proliferation, cell migration, the level of reactive oxygen species and promotes the activity of antioxidant enzymes in human lung epithelial adenocarcinoma cell line (A549),” Environ. Toxicol., May 2019. 
12. M. Maio et al., “Large randomized study of thymosin alpha 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma,” J. Clin. Oncol., vol. 28, no. 10, pp. 1780-1787, Apr. 2010. 
13. R. Daniel et al., “Thymosin α1 in melanoma: from the clinical trial setting to the daily practice and beyond,” Ann. N.Y. Acad. Sci., vol. 1270, pp. 8-12, Oct. 2012.
14. X. Shen et al., “Generation of a novel long-acting thymosin alpha1-Fc fusion protein and its efficacy for the inhibition of breast cancer in vivo,” Biomed. Pharmacother., vol. 108, pp. 610-617, Dec. 2018. 
15. F. Wang et al., “Thymosin Alpha1-Fc Modulates the Immune System and Down-regulates the Progression of Melanoma and Breast Cancer with a Prolonged Half-life,” Sci. Rep., vol. 8, no. 1, p. 12351, Aug. 2018. 
16. Y. Xu et al., “Thymosin Alpha-1 Inhibits Complete Freund's Adjuvant-induced Pain and Production of Microglia-Mediated Pro-inflammatory Cytokines in Spinal Cord,” Neurosci. Bull., Feb. 2019. 
17. L. Romani et al., “Thymosin α1 represents a potential potent single-molecule-based therapy for cystic fibrosis,” Nat. Med., vol. 23, no. 5, pp. 590-600, May 2017. 
18. P. F. Day, M. Duggal, and H. Nazzal, “Interventions for treating traumatised permanent front teeth: avulsed (knocked out) and replanted,” Cochrane Database Syst. Rev., vol. 2, p. CD006542, May 2019. 
19. M. Schmidt et al., “Design of a substrate-tailored peptiligase variant for the efficient synthesis of thymosin-α1,” Org. Biomol. Chem., vol. 16, no. 4, pp. 609-618, 2018.